4-(4-甲氧基苯胺)四氢-1(2H)-吡啶羧酸叔丁酯 | 306934-84-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-(4-甲氧基苯胺)四氢-1(2H)-吡啶羧酸叔丁酯
• 中文别名: N-BOC-4-(4-甲氧基苯胺基)哌啶
• 英文名称: tert-butyl 4-(4-methoxyphenylamino)piperidine-1-carboxylate
• 英文别名: tert-butyl 4-[(4-methoxyphenyl)amino]-piperidine-1-carboxylate；tert-butyl 4-[(4-methoxyphenyl)amino]piperidine-1-carboxylate；4-(p-anisidino)-1-(tert-butoxycarbonyl)piperidine；tert-butyl 4-(4-methoxyanilino)tetrahydro-1(2H)-pyridinecarboxylate；tert-butyl 4-(4-methoxyanilino)piperidine-1-carboxylate
• CAS: 306934-84-9
• 化学式: C₁₇H₂₆N₂O₃
• 分子量: 306.405
• InChiKey: ZSUFBKHEFBKBDJ-UHFFFAOYSA-N

物化性质

• 熔点：
  82 °C

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  50.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090
• 安全说明：
  S26,S36/37/39

SDS

Name:	tert-Butyl 4-(4-methoxyanilino)tetrahydro-1(2H)-pyridinecarboxylate Material Safety Data Sheet
Synonym:
CAS:	306934-84-9

Section 1 - Chemical Product MSDS Name:tert-Butyl 4-(4-methoxyanilino)tetrahydro-1(2H)-pyridinecarboxylate Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
306934-84-9	tert-Butyl 4-(4-methoxyanilino)tetrahy	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 306934-84-9: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: brown
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 76 - 82 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: Not available.
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C17H26N2O3
Molecular Weight: 306

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, reducing agents, acids, acid chlorides.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 306934-84-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
tert-Butyl 4-(4-methoxyanilino)tetrahydro-1(2H)-pyridinecarboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 306934-84-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 306934-84-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 306934-84-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(4-甲氧基苯胺)四氢-1(2H)-吡啶羧酸叔丁酯 在 盐酸 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 20.0h， 生成 N-(4-Methoxy-phenyl)-N-piperidin-4-yl-propionamide; hydrochloride
  参考文献：
  名称：

  蝶酮类似物的多步溶液相平行合成。

  摘要：

  描述了蝶啶类似物的灵活的多步平行合成。利用还原胺化和酰化方案组装的4-取代的哌啶文库利用仅产品释放的概念被均一或异质地烷基化，以提供oxa系列的spiperone类似物。对5-HT2和D2受体产物的筛选显示，与烯酮和AMI-193相比，选择性更高的5-HT2A拮抗剂。

  DOI：

  10.1016/s0960-894x(00)00483-2
• 作为产物：
  描述：

  1-Boc-4-氨基哌啶 在 titanium(IV) isopropylate 、 N-氯代丁二酰亚胺 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 4.41h， 生成 4-(4-甲氧基苯胺)四氢-1(2H)-吡啶羧酸叔丁酯
  参考文献：
  名称：

  使用伯胺和仲胺进行钛介导的格氏试剂的胺化

  摘要：

  制作，然后破坏它：使用标题转化法，在苯胺衍生物的合成中使用N-氯代琥珀酰亚胺（NCS）作为氧化剂（参见方案）。胺和格氏试剂均具有良好的功能性。雄激素受体激动剂和几种类似物被合成以证明该方法的实用性。

  DOI：

  10.1002/anie.201103700
• 作为试剂：
  描述：

  1-Boc-2-哌啶酮 、 甲氧苯胺 、 Sodium sulfate-III 、 三乙酰氧基硼氢化钠 在 sodium hydroxide 、 水 、 magnesium sulfate 、 4-(4-甲氧基苯胺)四氢-1(2H)-吡啶羧酸叔丁酯 作用下， 以 溶剂黄146 为溶剂， 反应 16.0h， 生成 4-(4-甲氧基苯胺)四氢-1(2H)-吡啶羧酸叔丁酯
  参考文献：
  名称：

  AMINOPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF

  摘要：

  本发明涉及公式(I)所定义的化合物，它们是黑色素细胞激素受体激动剂，涉及其制备和治疗用途，包括用于治疗和预防肥胖症、糖尿病和可能影响男女的性功能障碍，用于治疗心血管疾病，以及用于抗炎症或治疗酒精依赖症。

  公开号：

  US20070191364A1

文献信息

• Cyclic amine compounds and pharmaceutical composition containing the same
  申请人：KOWA CO., LTD.

  公开号：US20040010147A1

  公开（公告）日：2004-01-15

  A cyclic amine compound represented by the following general formula (1): 1 wherein, R 1 , R 2 and R 3 each independently represent a hydrogen atom or an alkoxy group; W 1 and W 2 each independently represent N or CH; X represents O, NR 4 , CONR 4 or NR 4 CO; R 4 represents a hydrogen atom, or an alkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl group; and l, m and n each represents a number of 0 or 1, a salt thereof and a hydrate thereof are provided. These compounds have inhibitory effects on both cell adhesion and cell infiltration and are useful as anti-asthmatic agents, anti-allergic agents, anti-rheumatic agents, anti-arteriosclerotic agents, anti-inflammatory agents, anti-Sjogren's syndrome agents or the like.

  以下是通用公式（1）表示的一个环胺化合物： 其中， R 1 ，R 2 和R 3 分别独立地表示氢原子或烷氧基； W 1 和W 2 分别独立地表示N或CH； X表示O，NR 4 ，CONR 4 或NR 4 CO； R 4 表示氢原子，或烷基，芳基，杂芳基，芳基烷基或杂芳基烷基； l，m和n分别表示0或1的数字， 提供其盐和水合物。 这些化合物对细胞粘附和细胞浸润均具有抑制作用，并可用作抗哮喘剂，抗过敏剂，抗风湿剂，抗动脉硬化剂，抗炎剂，抗干燥综合征剂等。
• 基于富电子氟代芳烃的胺化物及其制备方法
  申请人：华中师范大学

  公开号：CN110294685B

  公开（公告）日：2022-11-11

  本发明提供了基于富电子氟代芳烃的胺化物及其制备方法，所述胺化物具备式I所示结构。本发明还提供了基于富电子氟代芳烃的胺化物制备方法，具体为：在25℃，并在氩气的保护下，将化合物a与光敏剂和化合物b溶于有机溶剂中，使用蓝光照射48‑72小时，减压、蒸馏，柱层析、淋洗后得到所述胺化物。本申请所述制备方法利用了可见光介导的光氧化还原催化原理，相比于传统方法，它更为绿色环保、条件更为温和、更适合用作为富电子氟代芳烃的胺化。
• Nucleophilic Aromatic Substitution of Unactivated Aryl Fluorides with Primary Aliphatic Amines by Organic Photoredox Catalysis
  作者：Weimin Shi、Jingjie Zhang、Fengqian Zhao、Wei Wei、Fang Liang、Yin Zhang、Shaolin Zhou

  DOI：10.1002/chem.202002315

  日期：2020.11.20

  work, a mild and transition‐metal‐free approach for the nucleophilic aromatic substitution (SNAr) of unactivated fluoroarenes with primary aliphatic amines to form aromatic amines is reported. This reaction is facilitated by the formation of cationic fluoroarene radical intermediates in the presence of an acridinium‐based organic photocatalyst under blue‐light irradiation. Various electron‐rich and

  在这项工作中，对于亲核芳香取代温和和过渡金属无方法（S Ñ报道用脂族伯胺未活化fluoroarenes的氩），以形成芳族胺。blue啶基有机光催化剂在蓝光照射下，阳离子氟代芳烃自由基中间体的形成促进了该反应。各种富电子和电子中性的氟代芳烃都是胜任的亲电子试剂，可以进行这种转化。广泛的伯脂族胺，包括氨基酸酯，二肽以及直链和支链胺是合适的亲核试剂。几种复杂药物分子的后期功能化证明了该方案的综合实用性。
• Chemokine receptor binding compounds
  申请人：Zhou Yuanxi

  公开号：US20050277670A1

  公开（公告）日：2005-12-15

  The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. These compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

  本发明涉及化学因子受体结合化合物、制药组合物及其使用。更具体地，本发明涉及化学因子受体活性调节剂，优选为CCR5的调节剂。这些化合物表现出对人类免疫缺陷病毒（HIV）感染靶细胞的保护作用。
• Erythropoietin production accelerator
  申请人：Imagawa Shigehiko

  公开号：US20060040986A1

  公开（公告）日：2006-02-23

  The present invention relates to a preventive or therapeutic agent for pathological conditions caused by reduced production of erythropoietin, or for anemia, or for chronic anemia, renal anemia, aplastic anemia, or pure red cell aplasia, the agent comprising, as an active ingredient, a cyclic amine compound represented by the following formula (1): wherein, R 1 , R 2 and R 3 each independently represent a hydrogen atom, a halogen atom, or hydroxy, alkyl, halogen-substituted alkyl, alkoxy, alkylthio, carboxyl, alkoxycarbonyl or alkanoyl group; W 1 and W 2 each independently represent N or CH; X represents O, NR 4 , CONR 4 or NR 4 CO; R 4 each represents a hydrogen atom, or an alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heteroaralkyl group; and l, m and n each represents a number of 0 or 1, or a salt thereof or a solvate thereof.

  本发明涉及一种预防或治疗由于红细胞生成素减少引起的病理状态，或用于贫血，慢性贫血，肾性贫血，再生障碍性贫血或纯红细胞再生障碍的药物，该药物包含以下式（1）所表示的环状胺化合物作为活性成分：其中，R1，R2和R3各自独立地表示氢原子，卤素原子，羟基，烷基，卤代烷基，烷氧基，烷硫基，羧基，烷氧羰基或烷酰基；W1和W2各自独立地表示N或CH；X表示O，NR4，CONR4或NR4CO；R4表示氢原子，或烷基，烯基，炔基，取代或未取代芳基，取代或未取代杂芳基，取代或未取代芳基甲基，或取代或未取代杂芳基甲基基团；l，m和n各自表示0或1的数字，或其盐或溶剂化物。